"İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi"

During the past decade, Istanbul Universitesi Cerrahpasa Tip Fakultesi conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 18 clinical trials were completed, i.e. on average, 72% percent of trials that started reached the finish line to date. In the past 5 years, 10 clinical trials started and 14 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" #1 sponsor was "Boehringer Ingelheim" with 9 trials, followed by "Amgen" with 6 trials sponsored, "Bayer" with 5 trials sponsored, "Pfizer" with 4 trials sponsored and "Shire" with 4 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" #1 collaborator was "Astellas Pharma Inc" with 1 trials as a collaborator, "Medivation LLC, a wholly owned subsidiary of Pfizer Inc." with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" are "Ulcerative Colitis" (4 trials), "Prostate Cancer" (3 trials), "Crohn's Disease" (2 trials), "Idiopathic Pulmonary Fibrosis" (2 trials) and "Secondary Prevention" (2 trials). Many other conditions were trialed in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" in a lesser frequency.

Most popular intervention types in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" are "Drug" (30 trials), "Other" (6 trials), "Biological" (3 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "Ontamalimab" (3 trials), "dabigatran etexilate" (3 trials), "Apremilast" (2 trials) and "Degarelix" (2 trials). Other intervention names were less common.

The vast majority of trials in "Istanbul Universitesi Cerrahpasa Tip Fakultesi" are 29 trials for "All" genders, 5 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Istanbul Universitesi Cerrahpasa Tip Fakultesi". undefined are not yet recruiting, 7 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 22 completed trials in Istanbul Universitesi Cerrahpasa Tip Fakultesi, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Istanbul Universitesi Cerrahpasa Tip Fakultesi, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".